China Medical System 0867

China Medical System 0867

Postby winston » Mon Nov 29, 2010 11:54 am

Not vested

DJ MARKET TALK: Goldman Sachs Starts China Medical System At Buy
Nov 26, 2010

0947 [Dow Jones] STOCK CALL: Goldman Sachs starts China Medical System (0867.HK) at Buy, target price of HK$6.60 implies 25X FY11 P/E; stock also added to Conviction Buy list.

Forecasts above-average earnings CAGR of 37% in 2010-2012, driven by CMS' leading market position as third-party distributor in China's prescription market; sustainable revenue growth driven by new product launches; potential upside on additional in-licensed products, network expansion fueled by cash-rich position following recent IPO.

Source: Dow Jones Newswire
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118538
Joined: Wed May 07, 2008 9:28 am

Re: China Medical System 0867

Postby winston » Mon Nov 29, 2010 11:55 am

Not vested

DJ MARKET TALK: China Medical Service +13.6%; Take Profit - WFF
Sep 28, 2010


1454 [Dow Jones] NEW LISTING: China Medical Service (0867.HK) +13.6% at HK$5.75 vs IPO price of HK$5.06, supported by good response to its IPO with retail tranche of offer 85X oversubscribed.

"The early peak for the counter is higher when compared with the high yesterday based on its grey market price range. I think the recent strong trading sentiment in the equity market has lent support to the stock's debut," says Mark To at Wing Fung Financial.

Adds, outlook for medical and pharmaceutical firms looks strong and stable, but suggests taking profit as further upside likely limited.

Early high of HK$6.17 likely immediate cap, higher vs yesterday's high of HK$5.90 based on its grey market price range.


Source: Dow Jones Newswire
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118538
Joined: Wed May 07, 2008 9:28 am

Re: China Medical System 0867

Postby winston » Mon Nov 29, 2010 11:57 am

Not vested

DJ MARKET TALK: China Medical System +20%;Upbeat Industry Outlook
Sep 28, 2010

1114 [Dow Jones] NEW LISTING: China Medical System (0867.HK) +20.2% at HK$6.08 following strong IPO response with its retail tranche of offer 85X oversubscribed.

Prudential Brokerage's associate director Alvin Cheung says industry outlook for pharmaceutical sector positive as steady earnings growth expected, while company has exclusive rights to 8 key in-licensed products in China in a number of therapeutic areas.

"Stable earnings outlook supports the performance of the counter on its debut, but I think it's a good idea to reduce holding after its current gains, as there are more options in the near-term for new listings."

Source: Dow Jones Newswire
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118538
Joined: Wed May 07, 2008 9:28 am

Re: China Medical System 0867

Postby winston » Tue Dec 28, 2010 6:27 pm

Not vested

We raise our China Medical System 867 HK 2010/2011/2012 earnings estimates by 8.0%/8.5%/8.2% to US$29.4m, US$41.6m and US$55.4, respectively, to reflect lower operating costs by revising down sales and operating expense as percentage of revenue to 22.6%/ 22.1%/20.9% (from 24.8%/24.3%/23.1%), respectively, in 2010/2011/2012.

We overestimated the costs related to the recent IPO. We maintain Conviction Buy on CMS for its relatively attractive valuation against its robust earnings growth – the stock is currently trading at 20X 2011E P/E vs. sector average of 29X, with 37% EPS CAGR from 2010E-2012E vs. 24% peer average.

We raise our 12-month TP by 8.5% to reflect changes in our earnings estimates. Our revised EV/GCI-based TP of HK$7.2 (from HK$6.6) implies 23X 2011E P/E and 14% upside.

Source: GS
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118538
Joined: Wed May 07, 2008 9:28 am

Re: China Medical System 0867

Postby winston » Fri Aug 01, 2014 3:22 pm

not vested

<Research Report>CMS (00867.HK) maintained Buy with target raised to $11.3 by UBS

UBS, in its latest research report, said that after the discussion with the management of CMS (00867.HK), it believes the Company's 2014 earnings may rebound sharply by 23.8%.

CMS sales team was reorganized successfully; meanwhile, and the control of contract product will be strengthened, the earning growth over the next few years is believed to jump over 20%.

The target price is raised from $10.3 to $11.3, as the earning visibility increased.

The current stock price represents 2014/15 P/E of 21.7 times, which is attractive. The Buy rating is reiterated.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118538
Joined: Wed May 07, 2008 9:28 am

Re: China Medical System 0867

Postby winston » Fri Aug 01, 2014 3:24 pm

not vested

<Research Report>JPM: CMS (00867.HK) target lifted to $11 on higher growth
July 9, 2014

According to the latest research report by JP Morgan, it was believed that the growth momentum of profits will sustain when the productivity of CMS (00867.HK) is no longer restricted.

The bank anticipated revenue and net profit of the drug maker will jump 25% yearly in 2014.

Rating was retained at Overweight, due to the relatively low valuation.

Target price was lifted from $8.9 to $11.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118538
Joined: Wed May 07, 2008 9:28 am

Re: China Medical System 0867

Postby winston » Tue Apr 25, 2017 11:21 am

not vested

Why This Chinese Pharma Stock Is a Buy

By Daniel Shane

Drug distributor China Medical System (867.HK) was just prescribed a Buy rating by analysts at Jefferies.

In its initiation report, Jefferies said that shares in the Shenzhen-based company stood to rise by 13%.

CMS makes money by distributing third-party drugs that treat conditions ranging from hepatitis B to depression to hospitals and doctors.

Jefferies said catalysts for this stock include a recovery in sales of anti-depressant Deanxit and broader penetration of hypertension drug Plendil. It also points to new drug import rules in China that could encourage more foreign pharmaceutical companies to enter the world’ second biggest economy, which could provide new distribution opportunities for CMS.

As an aside, Barron’s Asia told readers to get a dose of the shares way back in September 2015, and they’ve returned a healthy 50% since.

Anyway, here’s a swab from the Jefferies report:

We think CMS should deliver stable growth near-to-mid term, and benefit in the long run from more licensing-in opportunities as a leader of third-party drug academic promotion in China.

We expect Deanxit to recover growth and Plendil to continue market penetration, and forecast 15%/16% sales/EPS CAGR in16-19E.

Jefferies’ price target on CMS is actually one of the more conservative of those covering the stock. Of the 15 analysts that follow the shares, the average price target is HKD15.44, or more than 15% upside.

The stock rallied as much as 1.8% this morning in Hong Kong trading.

Source: Barron's Asia

http://blogs.barrons.com/asiastocks/201 ... -is-a-buy/
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118538
Joined: Wed May 07, 2008 9:28 am


Return to C

Who is online

Users browsing this forum: No registered users and 7 guests

cron